Racura Oncology Ltd RAC

Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, reports the discovery of the primary mechanism of action (MOA) of its lead oncology asset, (E,E)-bisantrene. Bisantrene has a long clinical history of activity across a range of cancer indications, but its mechanism of action has been unknown.

Racura Oncology CEO & Managing Director Dr Daniel Tillett talked with Kerry Stevenson from Proactive at the the ASX Small and Mid-Cap Conference about the company’s expanding clinical pipeline and its strategy to tackle some of the biggest challenges in cancer treatment. Dr Tillett outlined three concurrent clinical programs currently underway, highlighting Racura’s diversified approach. The first program focuses on protecting the heart in patients undergoing chemotherapy using AC220, which has been progressing steadily for nearly a year. The second, the HARNESS-1 trial in lung cancer, is desi

As the Australian market experiences a potential commodities supercycle, driven by surges in metals like gold and silver, investor interest in materials is on the rise. Amid this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at accessible price points. Despite their vintage name, these stocks can still provide surprising value when they are backed by strong financial health and solid fundamentals.

As the Australian market navigates a mixed landscape with sectors like Materials showing strength while Energy struggles, investors are keenly observing potential opportunities. Penny stocks, though an older term, still represent an intriguing area of investment by highlighting smaller or less-established companies that may offer value. By focusing on those with robust financials and clear growth prospects, investors can uncover promising opportunities in this niche segment.

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett talked with Proactive about the company’s launch of two new clinical programs for its lead asset, RC220, targeting acute myeloid leukaemia (AML) and EGFR-mutated non-small cell lung cancer (NSCLC). Dr Tillett said the expansion marked “a really major step forward for the company”, highlighting how recent discoveries around RC220’s mechanism of action enabled a focused strategy in high-value cancer indications. The company has identified key markets where RC220 could delay or prevent resistance to existing therapies, creating strong p

The Australian market saw a flattish green day, with the ASX200 inching up by one-tenth of a percent as investors remained cautious amidst ongoing global economic uncertainties and fluctuating commodity prices. In such conditions, discerning investors often seek opportunities in lesser-known segments like penny stocks, which despite their outdated moniker, continue to offer intriguing prospects for growth. These stocks typically represent smaller or newer companies that can combine attractive...

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Race Oncology...